SMMT 250425 39.00P(SMMT250425P39000) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

Clear

All

Quotes

News

Learn

Help

All

News

Announcements

No matches yet

Operations too frequent. Please try again later.

Please check network settings and try again Refresh Refresh

History record

SMMT250425P39000

Watchlist

0.00
0.000.00%

15min DelayClose May 1 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Earnings Call Summary | Summit Therapeutics(SMMT.US) Q1 2025 Earnings Conference
moomoo AI35minutes ago · Conference Call
Summit Therapeutics Outlines Ivonescimab Progress With Key Phase III Data Expected Mid-2025
Seeking Alpha51minutes ago
Summit Therapeutics Non-GAAP EPS of -$0.07 Beats by $0.02
Seeking Alpha16:43 ET
Summit Therapeutics Q1 Loss Widens; Cash Equivalents Drop
MT Newswires16:32 ET
Earnings Flash (SMMT) Summit Therapeutics Q1 Adjusted Loss $0.07 Vs. $0.05 Loss Year Ago
MT Newswires16:17 ET
Summit Therapeutics | 10-Q: Quarterly report
SEC16:12 ET · Announcements

Comments

sg freeman

1 hour ago

$Summit Therapeutics (SMMT.US)$ insider all converting warrant at cost of 1.x with huge volume, this shit is going to drop tremendously

sg freeman

6 hours ago

$Summit Therapeutics (SMMT.US)$ only 360mil cash left to burn 1.5 year, zero revenue. this should be a penny stock

Adria87

Apr 26 14:59

$Summit Therapeutics (SMMT.US)$

Adria87

Apr 26 12:18

$Summit Therapeutics (SMMT.US)$ overreaction.. it will soon back to the previous price

In His GraceMercy

Apr 26 07:05

Disappointing HR in Interim OS Analysis

$Summit Therapeutics (SMMT.US)$
Akeso, Summit’s partner, released interim overall survival data for ivonescimab, a PD-1/VEGF bispecific antibody, in a Chinese Phase 3 trial (HARMONi-2) comparing it to Merck’s Keytruda for first-line PD-L1-positive non-small cell lung cancer (NSCLC). The hazard ratio for OS was reported as 0.777 (corrected from an initial 0.784), indicating a 22% reduction in the risk of death compared to Keytruda. However, this result was be...